Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about COGT, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2026-11-30 | bezuclastinib | GIST | NDA | 66% |
| 2026-12-30 | bezuclastinib | nonadvanced systemic mastocytosis | NDA | 66% |
| 2027-06-29 | bezuclastinib | advanced systemic mastocytosis | NDA | 66% |
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Sunitinib | Advanced Gastrointestinal Stromal Tumors | Phase 3 · NCT05208047 | Recruiting |
| Bezuclastinib (CGT9486) | Advanced Gastrointestinal Stromal Tumors | Phase 3 · NCT05208047 | Recruiting |
| FGFR2/3 Inhibitor CGT4859 | Intrahepatic Cholangiocarcinoma (Icc) | Phase 1/2 · NCT06777316 | Active not recruiting |
| Pexidartinib | Gastrointestinal Stromal Tumors | Phase 1/2 · NCT02401815 | Completed |
| ACTR T Cell Product | Solid Tumor | Phase 1 · NCT03680560 | Terminated |
| Anti-BCMA Antibody SEA-BCMA | Multiple Myeloma | Phase 1 · NCT03266692 | Terminated |
| PI3Ka H1047R Mutant Selective Inhibitor CGT6297 | PIK3CA Mutations | Phase 1 · NCT07383506 | Recruiting |
| HER2 Mutant-selective Inhibitor CGT4255 | Advanced Solid Tumor, Adult | Phase 1 · NCT07361562 | Recruiting |
| Autologous ACTR-CD16-CD28-expressing… | Lymphoma | Phase 1 · NCT03189836 | Terminated |
| Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced… | Lymphoma | Phase 1 · NCT02776813 | Completed |
Also used in these trials (approved or third-party drugs, not COGT's own candidates): Midazolam Hydrochloride, Trastuzumab, Rituximab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
COGT holds $791.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $79M/quarter from operations, an estimated runway of 30 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 37 · Moderate
We believe that our cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into late 2028, well past all three pending PDUFA action dates for bezuclastinib.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when COGT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR, LLC | Institution (13F) | 26,852,012 | 15.43% | 2026-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 13,593,063 | 7.81% | 2026-06-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 8,691,589 | 5.00% | 2026-06-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 8,131,026 | 4.67% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 7,770,149 | 4.47% | 2026-09-30 |
| Janus Henderson Group Ltd. | Institution (13F) | 7,432,956 | 4.27% | 2026-09-30 |
| Deerfield Management Company, L.P | Institution (13F) | 5,957,000 | 3.42% | 2026-09-30 |
| Fairmount Funds Management LLC Director · +39,414 options |
Insider | 5,503,418 | 3.16% | 2026-03-31 |
| Wellington Management Group, LLP | Institution (13F) | 4,677,224 | 2.69% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 4,477,194 | 2.57% | 2026-09-30 |
| Andrew R Robbins President and CEO, Director · +2.26M options |
Insider | 657,503 | 0.38% | 2026-05-19 |
| Cole Pinnow Chief Commercial Officer · +830,000 options |
Insider | 216,650 | 0.12% | 2025-12-17 |
Share count 173,994,452 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-10-01 filed 2026-10-05 |
Ferrante Karen Jean |
Option award (A) | 759 | – | – |
| 2026-08-27 filed 2026-08-31 |
Morris Arlene |
Option exercise (M) | 41,927 | – | – |
| 2026-08-27 filed 2026-08-31 |
Morris Arlene |
Option exercise (M) | 41,927 | $5.64 | 41,927 |
| 2026-08-27 filed 2026-08-31 |
Morris Arlene |
Option exercise (M) | 3,583 | $2.52 | 45,510 |
| 2026-08-27 filed 2026-08-31 |
Morris Arlene |
Sale (S) | 3,161 | $37.54 | 0 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for COGT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →